- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Lymphatic Tissues.
Displaying page 1 of 3.
EudraCT Number: 2018-000426-66 | Sponsor Protocol Number: 29BRC18.0036 | Start Date*: 2018-07-13 | |||||||||||
Sponsor Name:CHRU de Brest | |||||||||||||
Full Title: Aprepitant versus Hydroxyzine en association avec les traitements cytoréducteurs pour les patients avec néoplasies myéloprolifératives souffrant d’un Prurit Aquagénique Persistant. | |||||||||||||
Medical condition: néoplasies myéloprolifératives avec Prurit Aquagénique Persistant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005778-34 | Sponsor Protocol Number: Zevalin first line in FL | Start Date*: 2007-05-09 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin Berlin, Germany | |||||||||||||
Full Title: Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolida... | |||||||||||||
Medical condition: Patients with follicular lymphoma grade I-IIIa and stage III–IV (as well as for selected patients with extended abdominal stage II). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Ongoing) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005019-15 | Sponsor Protocol Number: CCTL019C2202 | Start Date*: 2018-11-08 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N... | |||||||||||||
Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005679-18 | Sponsor Protocol Number: GMX04 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:Bio Products Laboratory Limited | |||||||||||||
Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents | |||||||||||||
Medical condition: Primary immunodeficiency diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2017-003680-35 | Sponsor Protocol Number: 1652-CLTF | Start Date*: 2019-01-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Subtypes of Cutaneous T cell ltymphoma (CTCL): Mycosis Fungoides (MF) and Sézary Syndrome (SS) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) AT (Completed) GR (Completed) IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000677-89 | Sponsor Protocol Number: CIMJ995A12101 | Start Date*: 2022-11-18 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Phase I, open label, multicenter, dose escalation and expansion study of IMJ995 in Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004443-20 | Sponsor Protocol Number: HP-LY-CL-2063 | Start Date*: 2018-05-07 | |||||||||||||||||||||
Sponsor Name:Herantis Pharma Plc | |||||||||||||||||||||||
Full Title: A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph nod... | |||||||||||||||||||||||
Medical condition: Secondary lymphedema associated with the treatment of breast cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000838-39 | Sponsor Protocol Number: MHE104317 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd | |||||||||||||
Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome | |||||||||||||
Medical condition: Hypereosinophilic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NO (Completed) BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001257-31 | Sponsor Protocol Number: TACTIDA | Start Date*: 2021-08-25 | |||||||||||
Sponsor Name:Department of Pharmaceutical Biosciences, Uppsala University | |||||||||||||
Full Title: An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based ... | |||||||||||||
Medical condition: intermediate stage hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004113-85 | Sponsor Protocol Number: PA101-SM-02 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:Patara Pharma, LLC | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis | |||||||||||||
Medical condition: Indolent Systemic Mastocytosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002782-57 | Sponsor Protocol Number: IMIS2015-03 | Start Date*: 2016-11-22 |
Sponsor Name:Institut des maladies génétiques - Imagine | ||
Full Title: Phase 2 study of Brentuximab Vedotin associated with CHP followed by consolidation with high-dose therapy / autologous stem-cell transplantation as frontline treatment of patients with enteropathy-... | ||
Medical condition: enteropathy-associated T-cell lymphoma type 1 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000213-16 | Sponsor Protocol Number: Interfant-21 | Start Date*: 2022-09-21 | |||||||||||
Sponsor Name:Princess Máxima Center for Pediatric Oncology | |||||||||||||
Full Title: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia | |||||||||||||
Medical condition: Acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004915-30 | Sponsor Protocol Number: HO113 | Start Date*: 2013-09-05 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study. | ||||||||||||||||||
Medical condition: Graft Versus Host Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Ongoing) BE (Ongoing) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003237-33 | Sponsor Protocol Number: HO112 | Start Date*: 2013-11-21 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III t... | ||||||||||||||||||
Medical condition: Graft Versus Host Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004714-41 | Sponsor Protocol Number: GBG69 | Start Date*: 2012-05-18 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) | |||||||||||||
Medical condition: Patients with primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004489-32 | Sponsor Protocol Number: KVD900-201 | Start Date*: 2019-03-13 |
Sponsor Name:KalVista Pharmaceuticals Ltd | ||
Full Title: A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of ... | ||
Medical condition: Hereditary Angioedema Type I or II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) HU (Completed) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000136-59 | Sponsor Protocol Number: KVD824-201 | Start Date*: 2021-09-24 | ||||||||||||||||
Sponsor Name:Kalvista Pharmaceuticals Ltd | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Tre... | ||||||||||||||||||
Medical condition: Hereditary Angioedema Type I or II | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003272-13 | Sponsor Protocol Number: CP0201-NHL | Start Date*: 2021-10-27 | |||||||||||
Sponsor Name:CellPoint B.V. | |||||||||||||
Full Title: A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma | |||||||||||||
Medical condition: Relapsed/refractory B-cell non-Hodgkin lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001176-42 | Sponsor Protocol Number: KVD900-302 | Start Date*: 2022-09-30 | ||||||||||||||||
Sponsor Name:KalVista Pharmaceuticals Ltd | ||||||||||||||||||
Full Title: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with He... | ||||||||||||||||||
Medical condition: Hereditary Angioedema Type I or II | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) DE (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001226-21 | Sponsor Protocol Number: KVD900-301 | Start Date*: 2022-12-01 | ||||||||||||||||
Sponsor Name:KalVista Pharmaceuticals Ltd | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Dema... | ||||||||||||||||||
Medical condition: Hereditary Angioedema Type I or II | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) GR (Completed) IT (Ongoing) ES (Ongoing) NL (Completed) BG (Completed) PL (Completed) PT (Completed) SK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.